JOURNAL OF CLINICAL RESEARCH BEST PRACTICES
Vol. 10, No. 9, September 2014 "Happy Trials to You"

"PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2014/2015"

Mark P. Mathieu, editor, 2014, 421 pages, PAREXEL International, $425.00

Review by Norman M. Goldfarb

"PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2014/2015" is the industry's most complete compendium of statistics and other facts about drug development. The book includes hundreds of charts, tables, figures and analyses in six sections:

This book has been selected for

The First Clinical Research Bookshelf

Essential reading for clinical research professionals

- R&D Spending
- Products in Development
- Market Access/Reimbursement/Drug Pricing (new)
- Drug Development Costs/Complexity, Development Time, and Success Rates
- Regulatory/FDA Statistics
- International Statistics

A few of the fascinating findings in the book include the following:

- Global R&D ethical pharmaceutical R&D budgets averaged 17.8% of sales, a 34-year record high.
- Thirty-three percent of drug and biotech R&D projects are in oncology & immunomodulators, 15% are in systemic anti-infectives, and 14% are in central nervous system disorders, with no other area rising above 5%.
- As of January 2014, 11,307 drugs were in active development, a 7.9% increase over the previous year.
- There are 271 preventative and therapeutic vaccines in clinical development, with 146 for infectious diseases and 113 for cancer. Other notable areas are allergy and neurological disorders.
- Clinical trial complexity is highest in the Asia and Eastern Europe and lowest in Latin America and Western Europe.
- On average, the FDA approves novel therapies 44 days (14%) faster than the EMA.

The book is available at www.barnettinternational.com.

Reviewer

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information. Contact him at 1.650.465.0119 or ngoldfarb@firstclinical.com.